drugset / Trial / NCT05161715
Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
NaSingle-groupOpen-labelPrevention
Summary
A Phase 2a study in men and women with early Alzheimer's disease to evaluate the pharmacodynamics, pharmacokinetics and safety of obicetrapib therapy.
Timeline
- Start
- 2022-01-12
- Primary completion
- 2023-05-09
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obicetrapib | Small molecule | 10 mg | Oral |